A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Latest Information Update: 07 May 2024
At a glance
- Drugs Cemsidomide (Primary) ; Dexamethasone (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors C4 Therapeutics
- 30 Apr 2024 Planned End Date changed from 7 Dec 2024 to 7 Dec 2025.
- 30 Apr 2024 Planned primary completion date changed from 7 Sep 2024 to 7 Sep 2025.
- 22 Feb 2024 According to a C4 Therapeutics media release, as of February 2024, two dose levels are open for enrollment in the Phase 1/2 trial for R/R MM and one dose level open for enrollment in the Phase 1/2 trial for R/R NHL.